Medici announced that Medici Puya Pharmaceutical Technology Co., Ltd., a wholly-owned subsidiary of the company, was involved in a contractual dispute with Hongxu Biomedical Technology Co., Ltd., and the first instance of this lawsuit ruled that the subsidiary compensated the plaintiff 150,552 yuan in liquidated damages and rejected the plaintiff's other lawsuits; the subsidiary had withdrawn all counterclaims, and the court ruled to withdraw the lawsuit, and the subsidiary reserved the right to sue separately on matters relating to the counterclaim. This judgment is a first instance judgment. Both parties have the right to appeal within 15 days from the date the judgment is delivered. The case may enter a second trial. Investors are kindly requested to pay attention to investment risks.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.